Biofeedback for Adolescent Cannabis Use Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- be between the ages of 13 and 19 years, with a parent or legal guardian available to complete parental assessments, if the participant is a minor
- meet Diagnostic and Statistical Manual of Mental Disorders, 5th edition, (DSM-V) criteria for cannabis use disorder by clinical interview;
- be medically healthy;
- be willing to participate in the study intervention and assessments;
- plan to live locally for at least 4 months;
- be able to read English well enough to complete study questionnaires;
- have self-reported cannabis use in the past 28 days;
- have a Perceived Stress Scale score > 20.
Exclusion Criteria:
- current or past psychosis;
- bipolar I or II disorder;
- the need to take psychotropic medications at any time during the study;
- pregnancy;
- psychiatric or substance use disorder that cannot be managed with outpatient care (e.g. alcohol withdrawal, severe major depressive disorder, significant suicidal ideation); and
- medications known to affect HRV (e.g. albuterol, pseudoephedrine, beta adrenergic blockers).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Cognitive behavioral therapy (CBT) alone
|
|
|
Experimental: Cognitive behavioral therapy plus HRV biofeedback
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in Perceived Stress Scale
Time Frame: baseline and 16 weeks
|
baseline and 16 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in the number of days used marijuana in the past 28 days
Time Frame: baseline and 16 weeks
|
baseline and 16 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Christian Thurstone, M.D., Denver Health
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 13-0412
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.